Efficacy of oral levofloxacin and dirithromycin alone and in combination with rifampicin in the treatment of experimental murine Brucella abortus infection

International Journal of Antimicrobial Agents

Volumn 23, Issue 2, 2004, Pages 204-207

  Arda, Bilgin ^a   Tunçel, Mürşide ^a   Yaimazhan, Tansu ^a   Gökengin, Deniz ^a   Gürel, Özlem ^b  

^a EGE UNIVERSITY   (Turkey)

^b Izmir Sifa Hastanesi   (Turkey)

Author keywords

Animal model; Dirithromycin; Experimental murine brucellosis; Levofloxacin; Rifampicin

Indexed keywords

DIRITHROMYCIN; LEVOFLOXACIN; RIFAMPICIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BRUCELLA ABORTUS; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; INFECTION CONTROL; INOCULATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TISSUE CULTURE;

EID: 0842263807     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.07.005     Document Type: Article

References (15)

1. Report of the Turkish Ministry of Health, Division of Communicable Diseases, May 2001.
2. Young E.J. An overview of human brucellosis. Clin. Infect. Dis. 21:1995;283-290.
3. Akova M., Uzun Ö., Akalin H.E., Hayran M., Ünal S., Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob. Agents Chemother. 37:1993;1831-1834.
4. Ural O. Problems of therapy in brucellosis. Flora. 6:2001;5-11.
5. Lang R., Shasha B., Rubinstein E. Therapy of experimental murine brucellosis with streptomycin alone and combination with ciprofloxacin, doxycyline and rifampin. Antimicrob. Agents Chemother. 37:1993;2333-2336.
6. Phillipon M., Plommet M.G., Kazmierczak A., Marly J.L. Rifampicin in the treatment of experimental brucellosis in mice and guinea pigs. J. Infect. Dis. 136:1997;481-488.
7. Martin I., Sanchez E.G., Martinez I.M.et al. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob. Agents Chemother. 43:1999;194-195.
8. Fred T.C., Paul W.E., David A.et al. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob. Agents Chemother. 35:1991;1116-1126.
9. Isogai E., Isogai H., Hirose K.et al. Therapeutic effect of anti-TNF alpha antibody and levofloxacin in a mouse model of enterohemorrhagic Escherichia coli O157 infection. Comp. Immun. Microbiol. Infect. Dis. 2001;217-231.
10. Hooper C.D. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30:2000;243-254.
11. Gardia Rodriguez J.A., Munoz Bellino J.L., Fresnadillo M.J., Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob. Agents Chemother. 37:1993;911-913.
12. Brogen R.N., Peters D.H. Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 48:1994;599-616.
13. Philippon M., Plommet M.G., Kazmierczak A., Marly J.L. Rifampicin in the treatment of experimental brucellosis in mice and guinea pigs. J. Infect. Dis. 136:1977;482-488.
14. Shasha B., Lang R., Rubinstein E. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline and rifampin. Antimicrob. Agents Chemother. 36:1992;973-976.
15. Shasha B., Lang R., Rubinstein E. Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis. J. Antimicrob. Chemother. 33:1994;545-551.